TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer

This study tests TIL (tumor-infiltrating lymphocyte) therapy — where immune cells from the patient's own tumor are grown in a lab and reinfused — combined with immunotherapy drugs, for women with advanced or metastatic breast cancer that has not responded to standard treatments. TIL therapy is a personalized approach that uses the patient's own immune system to fight cancer more aggressively. **You may be eligible if...** - You are 16 to 90 years old with confirmed advanced, relapsed, or metastatic breast cancer - Your cancer has failed standard treatment or no standard treatment is available - You have a tumor accessible for biopsy to generate TIL therapy - You have at least one measurable tumor on a scan - You are in reasonably good health (Karnofsky score ≥60 or ECOG 0-2) - Your blood counts and organ function meet minimum thresholds **You may NOT be eligible if...** - You require high-dose daily steroids (more than 15mg prednisone) - You have active autoimmune disease requiring treatment - You are pregnant or not using adequate contraception - You have received other cancer treatments within 28 days of tumor removal for TIL - You have serious heart, kidney, or liver problems Talk to your doctor to see if this trial is right for you.